Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: An in silico based mechanism
10.1186/bcr2888
Saved in:
Main Authors: | Fuentes, G., Scaltriti, M., Baselga, J., Verma, C.S. |
---|---|
Other Authors: | BIOLOGICAL SCIENCES |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/101794 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore
by: Elaine Hsuen Lim, et al.
Published: (2024) -
Not all therapeutic antibody isotypes are equal: The case of IgM: Versus IgG in Pertuzumab and Trastuzumab
by: Samsudin, F., et al.
Published: (2021) -
Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer
by: Jitawatanarat,P., et al.
Published: (2015) -
Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer
by: Potjana Jitawatanarat, et al.
Published: (2018) -
Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma
by: Chong, Q.-Y, et al.
Published: (2020)